Tempus AI (TEM) said Thursday that it has expanded its partnership with Takeda Pharmaceutical (TAK) to support Takeda's oncology research and development using real-world multimodal datasets and biological model systems.
Financial terms of the new agreement were not provided.
Tempus AI said Takeda will use Tempus AI' real-world data and AI tools for its cancer therapeutic pipeline.
The companies have also initiated a multi-phase project using patient-derived tumor organoids linked to Tempus' genetic sequencing, aiming to improve drug candidate prioritization and effectiveness predictions, Tempus said.
Shares of Tempus were up 1.7% in recent premarket activity, while Takeda was marginally down by 0.2%.
Price: 50.16, Change: +1.01, Percent Change: +2.05
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。